Agios Pharmaceuticals (NASDAQ:AGIO) Lowered to “Sell” Rating by StockNews.com

StockNews.com downgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a hold rating to a sell rating in a report published on Friday.

AGIO has been the topic of a number of other research reports. Scotiabank raised their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Finally, Royal Bank of Canada raised their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $56.33.

Agios Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ:AGIO opened at $33.22 on Friday. The firm’s 50 day moving average is $35.19 and its two-hundred day moving average is $43.41. Agios Pharmaceuticals has a 52 week low of $24.88 and a 52 week high of $62.58. The firm has a market capitalization of $1.89 billion, a P/E ratio of 2.92 and a beta of 0.88.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 2,051.38% and a negative return on equity of 2.93%. Analysts predict that Agios Pharmaceuticals will post -0.46 EPS for the current year.

Insider Buying and Selling

In other news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares in the company, valued at $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.93% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AGIO. CWM LLC grew its stake in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 1,836 shares in the last quarter. Inspire Investing LLC boosted its holdings in shares of Agios Pharmaceuticals by 13.7% during the third quarter. Inspire Investing LLC now owns 9,228 shares of the biopharmaceutical company’s stock worth $410,000 after purchasing an additional 1,113 shares during the period. Creative Planning grew its position in Agios Pharmaceuticals by 35.8% during the third quarter. Creative Planning now owns 15,640 shares of the biopharmaceutical company’s stock valued at $695,000 after purchasing an additional 4,120 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 363 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in Agios Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,942 shares of the biopharmaceutical company’s stock worth $486,000 after buying an additional 4,272 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.